MedTrace Logo

Retrospective Study in Patients Receiving Two or More OZURDEX® Injections for Retinal Vein Occlusion (RVO)

NCT01411696 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 289

Last updated 2013-04-16

Study results available
· View outcomes & findings →

Summary

This is a retrospective data collection study to evaluate the efficacy, safety, and re-injection interval of OZURDEX® in the treatment of macular edema due to RVO. Following informed consent, there were no patient study visits. All data was collected via chart review.

Conditions

  • Retinal Vein Occlusion
  • Macular Edema

Interventions

DRUG

dexamethasone intravitreal implant 0.7 mg

Dexamethasone intravitreal implant 0.7 mg was dosed previously according to general clinical practice.

Sponsors & Collaborators

  • Allergan

    lead INDUSTRY

Principal Investigators

  • Medical Director · Allergan

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-07-31
Primary Completion
2012-03-31
Completion
2012-03-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01411696 on ClinicalTrials.gov